Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Toxicogenetics in drug development.

B K Park1, M Pirmohamed

  • 1Department of Pharmacology and Therapeutics, The University of Liverpool, P.O. Box 147, Ashton Street, L69 3GE, Liverpool, UK. bkpark@liv.ac.uk

Toxicology Letters
|April 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultra-low-dose computed tomography (CT) protocol for guiding cryoablation in treating a T1a renal cell carcinoma (RCC): radiation doses and treatment outcomes.

Clinical radiology·2025
Same author

Organ preservation after neoadjuvant long-course chemoradiotherapy versus short-course radiotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Theileria buffeli infections in grazing cattle in the Republic of Korea.

Tropical biomedicine·2021
Same author

Proteomic profiling of rectal cancer reveals acid ceramidase is implicated in radiation response.

Journal of proteomics·2018
Same author

Implications of HLA-allele associations for the study of type IV drug hypersensitivity reactions.

Expert opinion on drug metabolism & toxicology·2018
Same author

Exome sequencing of synchronously resected primary colorectal tumours and colorectal liver metastases to inform oncosurgical management.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2017
Same journal

hERG Channel Blockade and Additive Interactions of Magnolol and Honokiol from Magnolia Species.

Toxicology letters·2026
Same journal

Evaluation of dose-dependent hematotoxic effects of celastrol on human blood cells in vitro.

Toxicology letters·2026
Same journal

Environmental pharmaceutical and antibiotic mixtures: An exposomics-guided framework for mechanistic toxicology.

Toxicology letters·2026
Same journal

Size- and morphology-dependent cytotoxicity of metal-organic frameworks: Deciphering the structure-toxicity relationship.

Toxicology letters·2026
Same journal

Steroidogenesis suppression in H295R cells by 1,3-disubstituted ureas: A potential off-target effect of some sEH inhibitors.

Toxicology letters·2026
Same journal

Signaling pathways in tobacco smoking-induced cervical carcinogenesis: Beyond HPV-mediated activation.

Toxicology letters·2026
See all related articles

Leveraging genetic insights and technology advances personalized medicine by matching the right drug to the right patient. Toxicogenetics guides safe drug introduction and clinical practice, improving patient outcomes.

Area of Science:

  • Pharmacogenomics
  • Drug Development
  • Clinical Practice

Background:

  • Advances in understanding genetic variation in drug response offer new opportunities for safe drug introduction.
  • Personalized medicine aims to optimize drug selection based on individual benefit and risk factors.

Purpose of the Study:

  • To explore the integration of genetic analysis into drug development for ensuring safe clinical practice.
  • To discuss the strategic timing of genetic analysis based on event frequency and sample availability.

Main Methods:

  • Utilizing genetic analysis at various stages of drug development (Phases I-IV).
  • Employing retrospective studies for rare adverse events and prospective sample collection for future toxicogenetic analysis.
  • Integrating toxicogenetic findings into Specific Product Characteristics (SPC).

Related Experiment Videos

Main Results:

  • Common adverse events and efficacy can be assessed during Phases I-III.
  • Retrospective studies are crucial for understanding rare events like idiosyncratic toxicity.
  • Prospective sample collection enables analysis of rare adverse events identified in Phase IV.

Conclusions:

  • Toxicogenetics is essential for identifying genetically determined susceptibility to drug toxicity.
  • Incorporating toxicogenetic information into SPC is vital for clinical practice and drug safety.
  • This approach facilitates the contraindication of drugs in susceptible patient populations, enhancing safety.